Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Journal of Internal Medicine, EarlyView.Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello +3 more
wiley +1 more source
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials. [PDF]
PLoS OneSattar N +6 more
europepmc +1 more source
Beyond glycemic control: the neuroprotective potential of tirzepatide
Type 2 diabetes mellitus is linked to cognitive decline and an increased risk of neurodegenerative diseases. Tirzepatide, a medication that targets both the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has shown ...
Ali,Heba +3 more
core +1 more source
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Journal of Internal Medicine, EarlyView.Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of cirrhosis, hepatocellular carcinoma, and cardiometabolic morbidity. Often clinically silent until advanced fibrosis develops, management has largely relied on lifestyle interventions, with limited ...
Philip N. Newsome, Saima Ajaz
wiley +1 more source
Journal of Internal Medicine, EarlyView.Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund +5 more
wiley +1 more source
Beyond weight loss: Preserving muscle health in the incretin era
Journal of Diabetes Investigation, EarlyView.
Toshinori Imaizumi, Daisuke Yabe
wiley +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. [PDF]
Liver IntCusi K +5 more
europepmc +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, EarlyView.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report. [PDF]
Clin Case RepNejat C +4 more
europepmc +1 more source